FDA Warning Letter #738238: What the Empower Pharmacy Action Reveals About Compounded GLP-1s

A September 2026 Enforcement Action Puts 503A Exemptions Under the Microscope

The U.S. Food and Drug Administration issued Warning Letter No. 738238 to Empower Clinic Services, LLC (dba Empower Pharmacy) on September 18, 2026, following an inspection of the company’s Houston, Texas facility from November 3 through November 14, 2025. The letter, addressed to founder and CEO Arta Shaun Noorian, focuses on compounded semaglutide and tirzepatide formulations that the agency determined to be essentially copies of FDA-approved products.

The Products at Issue

FDA specifically identified three formulations in the warning letter: TIRZEPATIDE/NIACINAMIDE (4 ML)(17/2 MG/ML), SEMAGLUTIDE/CYANOCOBALAMIN (1 ML)(5/0.5 MG/ML), and TIRZEPATIDE/NIACINAMIDE (2.5 ML)(8/2 MG/ML). The agency stated these products “appear to be essentially copies of FDA-approved semaglutide and tirzepatide products” compounded “regularly and in inordinate amounts”.

The warning letter acknowledged that the firm submitted responses dated December 8, 2025, March 18, 2026, and April 30, 2026, but concluded that the compounded products still failed to satisfy Section 503A requirements.

The “Significant Difference” Problem

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounded drugs qualify for exemptions from certain FDA requirements—including premarket approval, adequate directions for use labeling, and current good manufacturing practice compliance—only if they meet specific statutory conditions. One critical condition is that a licensed pharmacist or physician must not compound regularly or in inordinate amounts any drug products that are essentially copies of commercially available drugs.

Section 503A(b)(2) provides an exception: a compounded product is not essentially a copy if “there is a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner”. This means the prescriber must document a genuine, patient-specific clinical rationale for the formulation change.

FDA’s inspection collected evidence that prescriptions lacked prescriber determinations of significant difference, while others contained determinations repeated verbatim across numerous records—suggesting they may have been pre-generated for prescriber selection. The agency also reviewed production records showing substantial dispensing activity, though specific numerical quantities are redacted in the public letter. FDA stated the volume suggested that differences between the compounded products and FDA-approved products were “pretextual”.

What This Means for 503A Pharmacies

The warning letter does not establish a blanket prohibition on compounded GLP-1 medications, but it demonstrates that FDA may scrutinize whether a pharmacy’s records actually substantiate individualized prescribing decisions—particularly when identical formulations and justifications appear across large numbers of prescriptions.

The practical takeaway for compounding pharmacies is straightforward: adding niacinamide, vitamin B12, or another ingredient does not, standing alone, satisfy the significant-difference standard. A fixed-dose vitamin across every strength is not clinical individualization. If the same justification sentence fits every patient, it documents nothing except that the prescriber knew the language was boilerplate.

The Broader Enforcement Context

The letter also addresses separate concerns involving sterile compounding practices, supporting records, and the effectiveness of corrective actions. For 503A pharmacies, the warning signals that FDA is examining the operational and documentary foundation supporting compounding activities—not just the formulations themselves.

Enforcement discretion for compounded tirzepatide ended March 5, 2025, and for compounded semaglutide on April 24, 2025. The Empower warning letter, issued more than a year after those dates, confirms that FDA is actively enforcing the post-shortage framework for these molecules.

The warning letter provides an opportunity for response and does not constitute a judicial determination resolving disputed facts or legal interpretations. However, it offers a clear view of FDA’s current enforcement posture: the documentation that was supposed to justify compounding can become the evidence that it was pretextual.